Hyperthermic intraperitoneal chemotherapy for the treatment of ovarian cancer: A brief overview of recent results

• The mentioned studies precludes definitive conclusion about the survival results.
• One randomized study only evaluated HIPEC in recurrent OC.
• To date, HIPEC must be included in clinical research and not in routine treatment.
• HIPEC seems well-tolerated when patient selection is appropriate.
• Morbidity and mortality are low in a referral center.

Ovarian cancer (OC) is the sixth most common neoplasm in women. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with maximal regional chemotherapy, has been proposed to treat OC. At present, less randomized trials has determined HIPEC real impact on patients with OC. In this brief report, we reported results of selected studies of treatment with HIPEC for patients with OC. Future prospects are conclusively discussed.